Table 2.

Incidence of trastuzumab-associated cardiac events in adjuvant breast cancer trials.

Trial	Number of patients in analysis	Treatment arm	Incidence of cardiac events (%)	Definition of cardiac event
NSABP B-31 (46, 51)	814	AC → P	0.8	NYHA class III/IV CHF or possible/probable cardiac death
	850	AC → PH	4.1
NCCTG N9831 (52)	664	AC → P	0.3	Symptomatic CHF or probably/definite cardiac death
	710	AC → P → H	2.8
	570	AC → PH	3.3
HERA (53)	1744	Chemotherapy	0.1	NYHA class III/IV CHF with decrease in LVEF ≥10% from baseline to LVEF <50%; or cardiac death
	1682	Chemotherapy + 1 year of Trastuzumab	0.8
	1673	Chemotherapy + 2 years of Trastuzumab	1.0
BCIRG 006 (48)	1073	AC → T	0.7	NYHA class III/IV CHF
	1074	AC → TH	2
	1075	TCH	0.4
FinHer (95)	116	Chemotherapy	1.7	Symptomatic heart failure
	115	Chemotherapy + Trastuzumab	0.9

AC, doxorubicin + cyclophosphamide; P, paclitaxel; H, trastuzumab; T, docetaxel; C, carboplatin.